tradingkey.logo

Merck Announces Positive Data From Phase 3 Trials Of Doravirine/Islatravir

ReutersMar 12, 2025 5:09 PM

- Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIALS THAT SHOW THE INVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN OF DORAVIRINE/ISLATRAVIR (DOR/ISL) MAINTAINED HIV-1 VIRAL SUPPRESSION AT WEEK 48

  • MERCK & CO INC - DOR/ISL SHOWS NON-INFERIORITY AND SIMILAR SAFETY PROFILE TO COMPARATORS

  • MERCK & CO INC - DOR/ISL MEETS PRIMARY EFFICACY AND SAFETY OBJECTIVES AT WEEK 48

  • MERCK & CO INC - PLANS TO BEGIN SUBMITTING APPLICATIONS FOR MARKETING AUTHORIZATION TO REGULATORY AGENCIES BY MID-2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI